# Verovaccines paves way for manufacturing its vaccines

- Verovaccines upscales manufacturing processes of its yeast-based vaccines to industrial scale
- This is an important milestone on the road to commercialization of this novel vaccine class

Halle (Saale), Germany, October 18, 2022 – German vaccine specialist Verovaccines GmbH is on its way to industrial-scale production. To this end, a series of controlled fermentation studies were conducted, which revealed exceptionally high reproducibility of the life yeast production system (see Figure). Low variation from run to run is key to a reliable production system for biopharmaceutical products such as vaccines.




**Excellent run-to-run fermentation reproducibility.** Data from three independent fermentation runs of a yeast-based bovine vaccine candidate show high consistency from run-to-run, as the data curves from all runs are superimposable. This high reproducibility also applies to other vaccine candidates containing other antigens or targeting other species, such as cattle (shown here), poultry, or swine (data not shown).

In addition, scale-up studies were initiated to move from the 5-liter laboratory scale to the industrial 300-1,000-liter scale. Together with two service providers, the company was able to successfully carry out this upscaling in just two fermentation runs. Already the first industrial run delivered a similar yield per liter as the lab scale and ran very stable from the beginning.

Managing Director Dr. Hanjo Hennemann: 'Based on the latest reproducibility and upscaling results, we are confident that we can complete the establishment of key production steps as planned.' Managing Director Prof. Sven-Erik Behrens adds, 'Furthermore, we expect to be able to easily upscale other yeast-based vaccines derived from our platform.'

###

**About Verovaccines GmbH**

Verovaccines is a spin-off of professor Sven-Erik Behrens, Ph.D., Hanjo Hennemann, Ph.D. and Martina Behrens, DVM from Martin Luther University Halle-Wittenberg. In addition to the

experienced founders, the company has a staff of scientists with expertise in the fields of virology, molecular biology, veterinary medicine, process development and project management. Several proprietary vaccine development programs are funded by the "Start-up Offensive Biotechnology", GO-Bio for short, of the Federal Ministry of Education and Research (BMBF).

**About Verovaccines' proprietary yeast-based vaccine platform**

Verovaccines' vaccines are based on a proprietary and patented technology platform using the milk yeast *Kluyveromyces lactis.* Several different immunity-inducing proteins (antigens) can be produced in a single yeast cell to produce low-cost combination vaccines. The vaccines contain complete, killed yeast cells that are made heat-stable by drying and can therefore be stored at room temperature. The technology is validated by demonstrating *Proof-of-Concept* in the respective target animals in six vaccine programs. Verovaccines is using its technology to develop a product pipeline of five vaccines against pathogens in pigs, cattle and poultry.

**Contact us:**

Verovaccines GmbH
Mareike Schünemann
Blücherstrasse 26
06120 Halle (Saale), Germany
E-mail: info@verovaccines.com
Web: www.verovaccines.com

VEROVACCiNES